Works matching Melphalan

Results: 2791

Anästhesiologisches und postinterventionelles Management bei perkutaner hepatischer Melphalanperfusion (Chemosaturation).

Published in:

Die Anaesthesiologie, 2023, v. 72, n. 2, p. 113, doi. 10.1007/s00101-022-01235-3

By:

Kliem, Peter;
Ebel, Sebastian;
Werdehausen, Robert;
Girrbach, Felix;
Bösemann, Denis;
van Bömmel, Florian;
Denecke, Timm;
Stehr, Sebastian;
Struck, Manuel F.

Publication type:

Article

Febrile reactions occurring with second cycle of high-dose melphalan and SCT in patients with AL amyloidosis: a ‘melphalan recall’ reaction.

Published in:

Bone Marrow Transplantation, 2010, v. 45, n. 1, p. 21, doi. 10.1038/bmt.2009.94

By:

Rosenzweig, M.;
Seldin, D. C.;
Remick, D. G.;
Skinner, M.;
Quillen, K.;
Oran, B.;
Finn, K. T.;
Sanchorawala, V.

Publication type:

Article

Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg/m2 conditioning regimens for autologous hematopoietic stem cell transplantation in patients with multiple myeloma: a systematic review and meta-analysis.

Published in:

2021

By:

Gao, Fei;
Lin, Mei-Si;
You, Jie-Shu;
Zhang, Min-Yue;
Cheng, Long;
Lin, Ke;
Zhao, Peng;
Chen, Qi-Yan

Publication type:

Literature Review

Hybrid Molecules of Benzylguanidine and the Alkylating Group of Melphalan: Synthesis and Effects on Neuroblastoma Cells.

Published in:

Journal of Clinical Medicine, 2023, v. 12, n. 13, p. 4469, doi. 10.3390/jcm12134469

By:

Bruchelt, Gernot;
Klose, Chihab;
Lischka, Matthias;
Brandes, Marietta;
Handgretinger, Rupert;
Brueckner, Reinhard

Publication type:

Article

Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen.

Published in:

Leukemia & Lymphoma, 2020, v. 61, n. 14, p. 3484, doi. 10.1080/10428194.2020.1811275

By:

Hagen, Patrick;
D'Souza, Anita;
Hari, Parameswaran;
Davila, Omar;
Zhang, Mei-Jie;
Vesole, David H.;
Smith, Scott E.;
Rodriguez, Tulio E.;
Stiff, Patrick J.

Publication type:

Article

Predictors of increased melphalan exposure correlate with overall survival, nonrelapse mortality, and toxicities in patients undergoing reduced-intensity allogeneic stem cell transplantation with fludarabine and melphalan.

Published in:

Journal of Oncology Pharmacy Practice, 2021, v. 27, n. 3, p. 579, doi. 10.1177/1078155220927436

By:

Sweiss, Karen;
Calip, Gregory Sampang;
Holden, Jaime;
Lewkowski, Paulina;
Mialik, Iryna;
Johnson, Jeremy;
Galvin, John P;
Rondelli, Damiano;
Patel, Pritesh

Publication type:

Article

Evaluating the adverse effects of melphalan formulations.

Published in:

Journal of Oncology Pharmacy Practice, 2019, v. 25, n. 7, p. 1631, doi. 10.1177/1078155218804042

By:

Xiang, Elaine;
Ni, Jian;
Glotzbecker, Brett;
Laubach, Jacob;
Soiffer, Robert;
McDonnell, Anne M

Publication type:

Article

Integrated Treatment during the Intravitreal Melphalan Era: Concurrent Intravitreal Melphalan and Systemic Chemoreduction.

Published in:

Ocular Oncology & Pathology, 2018, v. 4, n. 6, p. 334, doi. 10.1159/000486098

By:

Berry, Jesse L.;
Shah, Sona;
Kim, Fiona;
Jubran, Rima;
Kim, Jonathan W.

Publication type:

Article

Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015).

Published in:

Annals of Hematology, 2023, v. 102, n. 8, p. 2233, doi. 10.1007/s00277-023-05308-0

By:

Kim, Mihee;
Lee, Je-Jung;
Min, Chang-Ki;
Lee, Ji Yun;
Jo, Jae-Cheol;
Yoon, Sung-Soo;
Lim, Sung-Nam;
Do, Young Rok;
Kim, Kihyun;
Lee, Jae Hoon;
Yoo, Kwai Han;
Bae, Sung Hwa;
Yi, Jun Ho;
Jung, Jongheon;
Eom, Hyeon-Seok;
Jung, Sung-Hoon

Publication type:

Article

Improved survival after single-unit cord blood transplantation using fludarabine and melphalan-based reduced-intensity conditioning for malignant lymphoma: impact of melphalan dose and graft-versus-host disease prophylaxis with mycophenolate mofetil.

Published in:

Annals of Hematology, 2022, v. 101, n. 12, p. 2743, doi. 10.1007/s00277-022-04990-w

By:

Sakatoku, Kazuki;
Kim, Sung-Won;
Okamura, Hiroshi;
Kanaya, Minoru;
Kato, Koji;
Yamasaki, Satoshi;
Uchida, Naoyuki;
Kobayashi, Hikaru;
Fukuda, Takahiro;
Takayama, Nobuyuki;
Ishikawa, Jun;
Nakazawa, Hideyuki;
Sakurai, Masatoshi;
Ikeda, Takashi;
Kondo, Tadakazu;
Yoshioka, Satoshi;
Miyamoto, Toshihiro;
Kimura, Takafumi;
Ichinohe, Tatsuo;
Atsuta, Yoshiko

Publication type:

Article

Y90 -Ibritumomab tiuxetan (Y90 -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05).

Published in:

2017

By:

Voegeli, Michèle;
Rondeau, Stephanie;
Berardi Vilei, Simona;
Lerch, Erika;
Wannesson, Luciano;
Pabst, Thomas;
Rentschler, Jochen;
Bargetzi, Mario;
Jost, Lorenz;
Ketterer, Nicolas;
Bischof Delaloye, Angelika;
Ghielmini, Michele

Publication type:

journal article

Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial

Published in:

British Journal of Haematology, 2011, v. 153, n. 2, p. 212, doi. 10.1111/j.1365-2141.2011.08569.x

By:

Richardson, Paul;
Schlag, Rudolf;
Khuageva, Nuriet;
Dimopoulos, Meletios;
Shpilberg, Ofer;
Kropff, Martin;
Vekemans, Marie-Christiane;
Petrucci, Maria Teresa;
Rossiev, Viktor;
Hou, Jian;
Robak, Tadeusz;
Mateos, Maria-Victoria;
Anderson, Kenneth;
Esseltine, Dixie-Lee;
Cakana, Andrew;
Liu, Kevin;
Deraedt, William;
van de Velde, Helgi;
San Miguel, Jesús F.

Publication type:

Article

Solution stability of Captisol-stabilized melphalan (Evomela) versus Propylene glycol-based melphalan hydrochloride injection.

Published in:

Pharmaceutical Development & Technology, 2018, v. 23, n. 10, p. 1024, doi. 10.1080/10837450.2016.1265557

By:

Singh, Ramsharan;
Chen, Jin;
Miller, Teresa;
Bergren, Michael;
Mallik, Rangan

Publication type:

Article

High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation.

Published in:

British Journal of Clinical Pharmacology, 2016, v. 82, n. 1, p. 149, doi. 10.1111/bcp.12906

By:

Nath, Christa E.;
Trotman, Judith;
Tiley, Campbell;
Presgrave, Peter;
Joshua, Douglas;
Kerridge, Ian;
Kwan, Yiu Lam;
Gurney, Howard;
McLachlan, Andrew J.;
Earl, John W.;
Nivison‐Smith, Ian;
Zeng, Lihua;
Shaw, Peter J.

Publication type:

Article

Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.

Published in:

European Journal of Haematology, 2011, v. 86, n. 5, p. 372, doi. 10.1111/j.1600-0609.2011.01599.x

By:

Delforge, Michel;
Terpos, Evangelos;
Richardson, Paul G.;
Shpilberg, Ofer;
Khuageva, Nuriet K.;
Schlag, Rudolf;
Dimopoulos, Meletios A.;
Kropff, Martin;
Spicka, Ivan;
Petrucci, Maria T.;
Samoilova, Olga S.;
Mateos, Maria-Victoria;
Magen-Nativ, Hila;
Goldschmidt, Hartmut;
Esseltine, Dixie-Lee;
Ricci, Deborah S.;
Liu, Kevin;
Deraedt, William;
Cakana, Andrew;
van de Velde, Helgi

Publication type:

Article

Cost–utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma.

Published in:

European Journal of Haematology, 2001, v. 66, n. 5, p. 328, doi. 10.1034/j.1600-0609.2001.066005328.x

By:

Gulbrandsen, Nina;
Wisløff, Finn;
Nord, Erik;
Lenhoff, Stig;
Hjorth, Martin;
Westin, Jan

Publication type:

Article

Stability of Captisol-enabled versus propylene glycol–based melphalan at room temperature and after refrigeration.

Published in:

American Journal of Health-System Pharmacy, 2022, v. 79, n. 12, p. 1011, doi. 10.1093/ajhp/zxac055

By:

Kawedia, Jitesh D;
Ramchandran, Sumankalai;
Liu, Xiaoqian;
Gulbis, Alison M;
Titus, Mark;
Bashir, Qaiser;
Qazilbash, Muzaffar H;
Champlin, Richard E;
Ciurea, Stefan O

Publication type:

Article

VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection.

Published in:

Amyloid, 2004, v. 11, n. 4, p. 245, doi. 10.1080/13506120412331336907

By:

Gono, Takahisa;
Matsuda, Masayuki;
Shimojima, Yasuhiro;
Ishii, Wataru;
Koyama, Jun;
Sakashita, Kazuo;
Koike, Kenichi;
Hoshii, Yoshinobu;
Ikeda, Shu-ichi

Publication type:

Article

IgM AL amyloidosis due to B cell lymphoproliferative disorder: efficacy of high-dose melphalan followed by autologous stem cell transplantation.

Published in:

Amyloid, 2004, v. 11, n. 2, p. 130, doi. 10.1080/13506120410001725994

By:

Gono, Takahisa;
Matsuda, Masayuki;
Shimojima, Yasuhiro;
Ishii, Wataru;
Yamamoto, Kanji;
Koyama, Jun;
Sakashita, Kazuo;
Koike, Kenichi;
Itoh, Susumu;
Isaka, Toshifumi;
Ikeda, Shu-ichi

Publication type:

Article

Impact of concurrent gabapentin or pregabalin with high‐dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant.

Published in:

Pharmacotherapy, 2022, v. 42, n. 3, p. 233, doi. 10.1002/phar.2667

By:

Sivakumar, Akhilesh;
Bryson, Evan B.;
Hall, Kevin H.;
Maples, Kathryn T.;
Goyal, Subir;
Joseph, Nisha S.;
Hofmeister, Craig C.;
Kaufman, Jonathan L.;
Lonial, Sagar;
Nooka, Ajay K.;
Harvey, Robert Donald

Publication type:

Article

سنتز هیبرید پارتنولید و ملفالان و بررسی قدرت سمیت سلولی آن در برابر سلولهای سرطانی سینه

Published in:

Jundishapur Scientific Medical Journal, 2020, v. 19, n. 1, p. 11

By:

انسیه کریمی;
مهرداد ایرانشاهی;
علی الماسی راد;
احسان کریمی

Publication type:

Article

Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma.

Published in:

Bone Marrow Transplantation, 2011, v. 46, n. 4, p. 510, doi. 10.1038/bmt.2010.160

By:

Kazmi, S. M. A.;
Saliba, R. M.;
Donato, M.;
Wang, M.;
Hosing, C.;
Qureshi, S.;
Anderlini, P.;
Popat, U.;
Champlin, R. E.;
Giralt, S. A.;
Qazilbash, M. H.

Publication type:

Article

CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies.

Published in:

Bone Marrow Transplantation, 2010, v. 45, n. 12, p. 1699, doi. 10.1038/bmt.2010.49

By:

Holtan, S. G.;
Hogan, W. J.;
Elliott, M. A.;
Ansell, S. M.;
Inwards, D. J.;
Porrata, L. F.;
Johnston, P. B.;
Micallef, I. N.;
Lacy, M. Q.;
Gastineau, D. A.;
Litzow, M. R.

Publication type:

Article

High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: results of a single-institution randomized trial.

Published in:

Bone Marrow Transplantation, 2008, v. 41, n. 6, p. 547, doi. 10.1038/sj.bmt.1705925

By:

Papadimitriou, C.;
Dafni, U.;
Anagnostopoulos, A.;
Vlachos, G.;
Voulgaris, Z.;
Rodolakis, A.;
Aravantinos, G.;
Bamias, A.;
Bozas, G.;
Kiosses, E.;
Gourgoulis, G. M.;
Efstathiou, E.;
Dimopoulos, M. A.

Publication type:

Article

Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.

Published in:

Bone Marrow Transplantation, 2007, v. 40, n. 9, p. 843, doi. 10.1038/sj.bmt.1705801

By:

Nakamura, R.;
Rodriguez, R.;
Palmer, J.;
Stein, A.;
Naing, A.;
Tsai, N.;
Chang, K.;
Slovak, M. L.;
Bhatia, R.;
Spielberger, R.;
Kogut, N.;
Pullarkat, V.;
Kirschbaum, M.;
Forman, S. J.;
O'Donnell, M. R.

Publication type:

Article

Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.

Published in:

Bone Marrow Transplantation, 2006, v. 38, n. 7, p. 501, doi. 10.1038/sj.bmt.1705471

By:

Grazziutti, M. L.;
Dong, L.;
Miceli, M. H.;
Krishna, S. G.;
Kiwan, E.;
Syed, N.;
Fassas, A.;
Van Rhee, F.;
Klaus, H.;
Barlogie, B.;
Anaissie, E. J.

Publication type:

Article

Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect.

Published in:

Bone Marrow Transplantation, 2006, v. 37, n. 5, p. 455, doi. 10.1038/sj.bmt.1705271

By:

Dasgupta, R. K.;
Rule, S.;
Johnson, P.;
Davies, J.;
Burnett, A.;
Poynton, C.;
Wilson, K.;
Smith, G. M;
Jackson, G.;
Richardson, C.;
Wareham, E.;
Stars, A. C.;
Tollerfield, S. M.;
Morgan, G. J.

Publication type:

Article

Total body irradiation, fludarabine, melphalan, and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies.

Published in:

Bone Marrow Transplantation, 2006, v. 37, n. 5, p. 463, doi. 10.1038/sj.bmt.1705278

By:

Petropoulos, D.;
Worth, L. L.;
Mullen, C. A.;
Madden, R.;
Mahajan, A.;
Choroszy, M.;
Ha, C. S.;
Champlin, R. C.;
Chan, K. W.

Publication type:

Article

Melphalan 200?mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival.

Published in:

Bone Marrow Transplantation, 2005, v. 35, n. 10, p. 985, doi. 10.1038/sj.bmt.1704948

By:

Carlson, K

Publication type:

Article

Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate.

Published in:

Bone Marrow Transplantation, 2004, v. 34, n. 12, p. 1025, doi. 10.1038/sj.bmt.1704691

By:

Gertz, M. A.;
Lacy, M. Q.;
Dispenzieri, A.;
Ansell, S. M.;
Elliott, M. A.;
Gastineau, D. A.;
Inwards, D. J.;
Micallef, I. N. M.;
Porrata, L. F.;
Tefferi, A.;
Litzow, M. R.

Publication type:

Article

High-dose melphalan and autotransplantation followed by post transplant maintenance chemotherapy for acute lymphoblastic leukemia in first remission.

Published in:

Bone Marrow Transplantation, 2004, v. 33, n. 11, p. 1107, doi. 10.1038/sj.bmt.1704517

By:

Mehta, J.;
Powles, R.;
Sirohi, B.;
Treleaven, J.;
Kulkarni, S.;
Singhal, S.

Publication type:

Article

Treosulfan-Versus Melphalan-Based Reduced Intensity Conditioning in HLA-Haploidentical Transplantation for Patients ≥ 50 Years with Advanced MDS/AML.

Published in:

Cancers, 2024, v. 16, n. 16, p. 2859, doi. 10.3390/cancers16162859

By:

Fraccaroli, Alessia;
Stauffer, Elena;
Haebe, Sarah;
Prevalsek, Dusan;
Weiss, Lena;
Dorman, Klara;
Drolle, Heidrun;
von Bergwelt-Baildon, Michael;
Stemmler, Hans-Joachim;
Herold, Tobias;
Tischer, Johanna

Publication type:

Article

Prognostic Factors for Postoperative Bleeding Complications and Prolonged Intensive Care after Percutaneous Hepatic Chemosaturation Procedures with Melphalan.

Published in:

Cancers, 2023, v. 15, n. 15, p. 3776, doi. 10.3390/cancers15153776

By:

Struck, Manuel Florian;
Werdehausen, Robert;
Kirsten, Holger;
Gössmann, Holger;
Veelken, Rhea;
van Bömmel, Florian;
Stehr, Sebastian;
Denecke, Timm;
Ebel, Sebastian

Publication type:

Article

Percutaneous Hepatic Perfusion (PHP) with Melphalan in Liver-Dominant Metastatic Uveal Melanoma: The German Experience.

Published in:

Cancers, 2022, v. 14, n. 1, p. 118, doi. 10.3390/cancers14010118

By:

Dewald, Cornelia L. A.;
Warnke, Mia-Maria;
Brüning, Roland;
Schneider, Martin A.;
Wohlmuth, Peter;
Hinrichs, Jan B.;
Saborowski, Anna;
Vogel, Arndt;
Wacker, Frank K.

Publication type:

Article

Whole Lung Irradiation after High-Dose Busulfan/Melphalan in Ewing Sarcoma with Lung Metastases: An Italian Sarcoma Group and Associazione Italiana Ematologia Oncologia Pediatrica Joint Study.

Published in:

Cancers, 2021, v. 13, n. 11, p. 2789, doi. 10.3390/cancers13112789

By:

Abate, Massimo E.;
Cammelli, Silvia;
Ronchi, Letizia;
Diletto, Barbara;
Gandola, Lorenza;
Paioli, Anna;
Longhi, Alessandra;
Palmerini, Emanuela;
Puma, Nadia;
Tamburini, Angela;
Mascarin, Maurizio;
Coassin, Elisa;
Prete, Arcangelo;
Asaftei, Sebastian D.;
Manzitti, Carla;
Bisogno, Gianni;
Pierobon, Marta;
Coccoli, Luca;
Capasso, Mariella;
Grignani, Giovanni

Publication type:

Article

Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells.

Published in:

Cancers, 2019, v. 11, n. 4, p. 439, doi. 10.3390/cancers11040439

By:

Gourzones, Claire;
Bellanger, Céline;
Lamure, Sylvain;
Gadacha, Ouissem Karmous;
De Paco, Elvira Garcia;
Vincent, Laure;
Cartron, Guillaume;
Klein, Bernard;
Moreaux, Jérôme

Publication type:

Article

Complete Remission of a Refractory Acute Myeloid Leukemia with Myelodysplastic- and Monosomy 7-Related Changes after a Combined Conditioning Regimen of Plerixafor, Cytarabine and Melphalan in a 4-Year-Old Boy: A Case Report and Review of Literature.

Published in:

Cancers, 2018, v. 10, n. 9, p. 291, doi. 10.3390/cancers10090291

By:

Grasso, Antonio G.;
Granzotto, Marilena;
Zanon, Davide;
Maestro, Alessandra;
Loiacono, Stefano;
Maximova, Natalia

Publication type:

Article

Superselective intra-arterial melphalan therapy for newly diagnosed and refractory retinoblastoma: results from a single institution.

Published in:

Clinical Ophthalmology, 2013, v. 7, p. 981, doi. 10.2147/OPTH.S43398

By:

Thampi, Sheila;
Hetts, Steven W.;
Cooke, Daniel L.;
Stewart, Paul J.;
Robbins, Elizabeth;
Banerjee, Anuradha;
DuBois, Steven G.;
Char, Devron;
Halbach, Van;
Matthay, Katherine

Publication type:

Article

Complete response to orally administered melphalan in malignant pleural effusion from an occult female genital organ primary neoplasm with BRCA1/2 mutations: a case report.

Published in:

2018

By:

Fan, Frank S.;
Yang, Chung-Fan

Publication type:

journal article

Diffuse chorioretinal atrophy after a single standard low- dose intravitreal melphalan injection in a child with retinoblastoma: a case report.

Published in:

2016

By:

An-Ning Chao;
Ling-Yuh Kao;
Liu, Laura;
Nan-Kai Wang;
Chao, An- Ning;
Kao, Ling-Yuh;
Wang, Nan-Kai

Publication type:

journal article

Fludarabine and melphalan conditioning with tacrolimus as GVHD prophylaxis for allogeneic stem cell transplant recipients is an effective reduced-intensity combination regimen compared to the conventional regimen.

Published in:

International Journal of Clinical Oncology, 2009, v. 14, n. 3, p. 197, doi. 10.1007/s10147-008-0826-7

By:

Imataki, Osamu;
Ohnishi, Hiroaki;
Ohbayashi, Yumiko;
Kitanaka, Akira;
Kubota, Yoshitsugu;
Ishida, Toshihiko;
Tanaka, Terukazu

Publication type:

Article

A case report: high dose melphalan as a conditioning regimen for multiple myeloma induces sinus arrest.

Published in:

Cardio-Oncology, 2020, v. 6, n. 1, p. 1, doi. 10.1186/s40959-020-0059-0

By:

Ma, Liang-Liang;
Liu, Ying;
Jia, Si-Xun;
Lv, Hai-Chen;
Fang, Mei-Yun;
Xia, Yun-Long

Publication type:

Article

Development and Validation of an HPLC- UV Method for the Determination of Melphalan from Lyophilized Nanosuspension.

Published in:

Indian Journal of Pharmaceutical Education & Research, 2019, v. 53, n. 2, p. 316, doi. 10.5530/ijper.53.2.40

By:

Ashok, Powar Trupti;
Ananda, Hajare Ashok

Publication type:

Article

Comparison of intravitreal melphalan with and without topotecan in the management of vitreous disease in retinoblastoma.

Published in:

Japanese Journal of Ophthalmology, 2020, v. 64, n. 4, p. 351, doi. 10.1007/s10384-020-00743-2

By:

Kiratli, Hayyam;
Koç, Irem;
Öztürk, Ebru;
Varan, Ali;
Akyüz, Canan

Publication type:

Article

Intravitreal injection of melphalan for intraocular retinoblastoma.

Published in:

Japanese Journal of Ophthalmology, 2015, v. 59, n. 3, p. 164, doi. 10.1007/s10384-015-0378-0

By:

Suzuki, Shigenobu;
Aihara, Yukiko;
Fujiwara, Miyuki;
Sano, Shuichi;
Kaneko, Akihiro

Publication type:

Article

Selective ophthalmic arterial injection of melphalan for intraocular retinoblastoma: a 4-year review.

Published in:

Japanese Journal of Ophthalmology, 2015, v. 59, n. 2, p. 109, doi. 10.1007/s10384-014-0356-y

By:

Ong, Sherine;
Chao, An-Ning;
Wong, Ho-Fai;
Liou, Kuan-Lyin;
Kao, Ling-Yuh

Publication type:

Article

Increased risk of gastrointestinal acute GVHD following the addition of melphalan to busulfan/cyclophosphamide conditioning.

Published in:

Pediatric Transplantation, 2013, v. 17, n. 3, p. 285, doi. 10.1111/petr.12061

By:

Mårtensson, T.;
Priftakis, P.;
Casswall, T.;
Ringdén, O.;
Mattsson, J.;
Remberger, M.;
Hassan, M.;
Gustafsson, B.

Publication type:

Article

Low toxicity and efficacy of153samarium-EDTMP and melphalan as a conditioning regimen for secondary acute myelogenous leukemia.

Published in:

Pediatric Transplantation, 2005, v. 9, n. 1, p. 122, doi. 10.1111/j.1399-3046.2005.00248.x

By:

Rodriguez, Vilmarie;
Erlandson, Linda;
Arndt, Carola A. S.;
Wiseman, Gregory A.;
Anderson, Peter M.

Publication type:

Article

The αVβ3/αVβ5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model.

Published in:

International Journal of Cancer, 2013, v. 132, n. 11, p. 2694, doi. 10.1002/ijc.27940

By:

ten Hagen, Timo L.M.;
Seynhaeve, Ann L.B.;
de Wiel‐Ambagtsheer, Gisela aan;
de Bruijn, Ernst A.;
van Tiel, Sandra T.;
Ruegg, Curzio;
Meyring, Michael;
Grell, Matthias;
Goodman, Simon L.;
Eggermont, Alexander M.M.

Publication type:

Article

A comparison of the in vitro Genotoxicity of Anticancer Drugs Melphalan and Mitoxantrone.

Published in:

American Journal of Biomedical Sciences, 2013, v. 5, n. 3, p. 171, doi. 10.5099/aj130300171

By:

Mishra, Susmita;
Mishra, Ravi Prakash

Publication type:

Article